T cell receptor – peptide–major histocompatibility complex (TCR-pMHC)

The T cell receptor – peptide–major histocompatibility complex (TCR-pMHC) is the fundamental molecular assembly that governs the adaptive immune system's ability to recognize and respond to specific antigens. This complex is formed when a T cell receptor (TCR) on the surface of a T lymphocyte binds to a peptide fragment derived from intracellular or extracellular proteins, which is presented by a major histocompatibility complex (MHC) molecule—referred to as human leukocyte antigen (HLA) in humans—on the surface of an antigen-presenting cell or a tumor cell (Source: PubMed, PMID: 28234348). The specificity of this interaction allows T cells to distinguish between self-proteins and those derived from pathogens or mutated cancer cells (Source: UniProt, P01850). In modern immunotherapy, the TCR-pMHC complex is a critical target for TCR-engineered T-cell (TCR-T) therapies and bispecific T-cell engagers, which are designed to redirect the immune system against specific tumor-associated peptides (Source: NIH, National Cancer Institute). These approaches are particularly significant because they allow for the targeting of intracellular antigens, which are typically inaccessible to conventional antibody-based therapies that only recognize surface proteins (Source: Nature Reviews Drug Discovery, 2021). However, therapeutic targeting of this complex requires precise HLA matching and carries risks of off-target cross-reactivity if the targeted peptide sequence is similar to those found in healthy tissues (Source: FDA, Kimmtrak Prescribing Information).

Other names

TCR-pMHC complexT-cell receptor-antigen complexTCR-peptide-HLA complexTCR-pHLA complexTCR-antigen-MHC complex

Therapeutic agents targeting the TCR-pMHC complex generally fall into two categories: TCR-engineered T-cell (TCR-T) therapies and soluble bispecific TCR molecules. TCR-T therapies involve genetically modifying a patient's T cells to express a specific TCR that recognizes a tumor-associated pMHC. Bispecific molecules, such as Immune Mobilizing Monoclonal TCRs Against Cancer (ImmTACs), utilize a high-affinity soluble TCR to bind the pMHC on a target cell and an anti-CD3 effector domain to recruit and activate polyclonal T cells, bypassing the need for endogenous TCR recognition to induce target cell lysis.